Rate of Viral Evolution and Risk of Losing Future Drug Options in Heavily Pretreated, HIV-Infected Patients Who Continue to Receive a Stable, Partially Suppressive Treatment Regimen | Zendy

Hiroyu Hatano | Zendy; Peter W. Hunt | Zendy; Jodi Weidler | Zendy; Eoin Coakley | Zendy; Rebecca Hoh | Zendy; Teri Liegler | Zendy; Jeffrey N. Martin | Zendy; Steven G. Deeks | Zendy

Open Access

Rate of Viral Evolution and Risk of Losing Future Drug Options in Heavily Pretreated, HIV-Infected Patients Who Continue to Receive a Stable, Partially Suppressive Treatment Regimen

Author(s) -

Hiroyu Hatano,

Peter W. Hunt,

Jodi Weidler,

Eoin Coakley,

Rebecca Hoh,

Teri Liegler,

Jeffrey N. Martin,

Steven G. Deeks

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/508655

Subject(s) - medicine , regimen , viral load , drug resistance , population , resistance mutation , protease inhibitor (pharmacology) , cohort , mutation , virology , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , reverse transcriptase , biology , genetics , polymerase chain reaction , environmental health , gene

Many treatment-experienced, HIV-infected patients who have limited therapeutic options for complete viral suppression continue to receive a partially suppressive treatment regimen pending the availability of at least 2 new antiretroviral drugs. The major risk of this approach is ongoing viral evolution and the loss of future drug options.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research